Prostate cancer treatment worth $40,000 a year to be on PBS
Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June, which currently costs patients about $40,000 a year.
health